CDSCO Approves Novo Nordisk's Wegovy for Fatty Liver Disease in India
New Delhi: Novo Nordisk India on Friday said it has received approval from the Central Drugs Standard Control Organisation for indication of its Wegovy injection for the treatment of fatty liver disease in India.
The Central Drugs Standard Control Organisation (CDSCO) has approved a new indication for Wegovy (semaglutide injection 2.4 mg), Novo Nordisk India said in a statement.
It makes Wegovy the first and only GLP-1 RA to be approved both globally and in India for the treatment of noncirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis along with a reduced calorie diet and increased physical activity, it added.
MASH is a liver disease that develops due to excess fat buildup in the liver, causing chronic inflammation and liver damage.
Novo Nordisk India MD Vikrant Shrotriya said the burden of MASH continues to rise in India, but treatment options are still severely limited. People with MASH face a higher risk of serious liver complications and heart-related disease.
"This approval is an important milestone, giving doctors and patients a new option for people at risk of MASH while also helping to address obesity and related heart and metabolic diseases," he added.
Wegovy is also indicated for treatment of type 2 diabetes mellitus and in chronic weight management in adults.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.